Auricularia Polysaccharides and Macrophage Activation

Auricularia and Immunity

6 preclinical studies

Six studies published between 2012 and 2024 demonstrate that polysaccharides from Auricularia species activate macrophages through TLR4-mediated signaling, enhancing phagocytosis, nitric oxide production, and pro-inflammatory cytokine release.

Perera et al., Carbohydrate Polymers, 2020

TLR4/NF-kB

primary signaling pathway identified

RAW264.7

most-used macrophage cell line in these studies

0 human trials

all evidence from cell culture or animal models

Perera et al., Carbohydrate Polymers, 2020

View as image ↗

Macrophages are the immune system's first responders. They engulf pathogens, debris, and damaged cells through phagocytosis, then recruit other immune cells by releasing cytokines and nitric oxide. Six preclinical studies published between 2012 and 2024 have tested whether polysaccharides extracted from Auricularia species (wood ear mushrooms) can enhance these macrophage functions. The answer, consistently, is yes in the laboratory setting. Perera et al. (2020) demonstrated that glucuronoxylomannan from Auricularia auricula-judae increased macrophage phagocytic capacity and bactericidal activity through Toll-like receptor 4 (TLR4) signaling.^[1] For the broader picture of wood ear and immune function, see wood ear and the immune system and Auricularia polysaccharides and immune cell activation.

All six studies used macrophage cell lines (primarily RAW264.7 mouse macrophages) or animal models. No human trial has tested Auricularia polysaccharides for immune enhancement. The gap between activating mouse macrophages in a dish and meaningfully enhancing human immune function after oral consumption is large and unaddressed.

TLR4 recognition: how macrophages detect Auricularia polysaccharides

Toll-like receptor 4 (TLR4) sits on the macrophage surface and recognizes pathogen-associated molecular patterns, most famously bacterial lipopolysaccharide (LPS). Two studies from Perera's group established that Auricularia polysaccharides activate macrophages through the same receptor.

Perera et al. (2018) isolated glucuronoxylomannan from Auricularia auricula-judae and demonstrated that its immunostimulatory activity depended on specific structural features. Removing carboxylic acid groups (by reduction) or O-acetyl groups (by alkaline treatment) abolished the ability to stimulate TNF-alpha and IL-6 production in macrophages. Using TLR4-knockout cells and anti-TLR4 antibodies, the group confirmed that immunostimulation required TLR4 binding.^[2]

The follow-up study (Perera et al., 2020) mapped the downstream signaling cascade. After TLR4 engagement, the polysaccharide activated reactive oxygen species (ROS) production, mitogen-activated protein kinases (MAPK), and protein kinase C-alpha (PKC-alpha). These converged on NF-kB, the master transcription factor for inflammatory gene expression. The same study measured functional outcomes: treated macrophages showed increased phagocytosis of neutral red dye and enhanced killing of internalized bacteria.^[1]

An unexpected finding was endotoxin tolerance. Macrophages pre-treated with the Auricularia polysaccharide showed reduced responsiveness to subsequent LPS challenge, producing less TNF-alpha and IL-6 upon re-stimulation.^[1] This tolerance phenomenon mirrors what happens after bacterial infection, where initial immune activation is followed by a refractory period that prevents excessive inflammation. Whether this is beneficial (preventing cytokine storms) or detrimental (reducing pathogen defense) depends entirely on context.

Macrophage activation: NO, cytokines, and phagocytosis

Bao et al. (2020) isolated a polysaccharide from Auricularia auricula, characterized it structurally, and tested its effects on RAW264.7 macrophages. The purified fraction was a galactan with an average molecular weight of 23.51 kDa, composed primarily of mannose, glucose, galactose, arabinose, and fucose subunits.^[3]

Treatment produced three measurable outcomes in dose-dependent fashion. First, macrophage proliferation increased, measured by MTT assay. Second, nitric oxide (NO) production increased, measured by Griess reagent. NO is a key antimicrobial molecule that macrophages use to kill intracellular pathogens. Third, phagocytic capacity increased, measured by neutral red uptake. The phagocytosis enhancement was the most functionally relevant finding, as it directly measures the macrophage's ability to engulf and internalize particles.^[3]

The study did not identify the receptor or signaling pathway responsible, but the dose-dependent pattern and the combination of NO production with phagocytosis enhancement are consistent with TLR4-mediated activation seen in Perera's studies. For comparison with how other mushroom polysaccharides activate similar pathways, see Agaricus blazei polysaccharide and Toll-like receptor activation.

Sulfation enhances immunostimulatory potency

Nguyen et al. (2012) tested whether chemical modification of Auricularia polysaccharides could amplify their immune effects. They prepared sulfated derivatives by introducing sulfate groups onto the polysaccharide backbone and compared these against the native (non-sulfated) form.^[4]

Sulfated Auricularia polysaccharides showed greater immunostimulatory activity across multiple measures: increased macrophage NO production, elevated secretion of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), and enhanced splenocyte proliferation in culture. The degree of sulfation correlated with activity, with higher sulfate content producing stronger responses.^[4]

This finding has two implications. Practically, it suggests that chemical modification could produce more potent immunostimulatory preparations from Auricularia than the natural polysaccharide provides. Scientifically, it supports the idea that negative charges on the polysaccharide surface (from sulfate or carboxylic acid groups, as shown by Perera et al., 2018) are critical for receptor recognition. The TLR4 binding site that recognizes LPS also relies on the negative charge of LPS phosphate groups, which sulfate groups may mimic.

M1 macrophage polarization and anti-tumor effects

Macrophages exist on a spectrum between two polarization states. M1 macrophages are pro-inflammatory, antimicrobial, and anti-tumor. M2 macrophages are anti-inflammatory, tissue-repairing, and, in the tumor microenvironment, often tumor-promoting. Tumors actively recruit and convert macrophages to the M2 phenotype to evade immune destruction.

Nilkhet et al. (2024) tested whether crude polysaccharides from Auricularia polytricha could push macrophages toward the M1 state. They treated RAW264.7 macrophages with polysaccharide extracts and measured expression of M1-associated genes and cytokines. The treatment upregulated IL-6, IL-1beta, TNF-alpha, iNOS, and other M1 markers in a dose-dependent manner. NF-kB pathway activation was confirmed as the mechanism.^[5]

The study then asked a functional question: can these M1-polarized macrophages inhibit cancer cell growth? Conditioned media from polysaccharide-treated macrophages (containing their secreted cytokines and factors) was applied to MDA-MB-231 and MCF-7 human breast cancer cells. The conditioned media reduced breast cancer cell viability by approximately 40-60% compared to media from untreated macrophages.^[5]

This is an indirect anti-tumor mechanism. The polysaccharides did not kill cancer cells directly. They activated macrophages, and the activated macrophages secreted factors that killed cancer cells. Whether this cascade could function in a living organism, where tumor-derived immunosuppressive signals constantly push macrophages toward M2, is entirely speculative at this point. For how other mushroom compounds approach anti-tumor immunity, see Antrodia polysaccharides and immune enhancement.

In vivo evidence: reversing immunosuppression in mice

Kong et al. (2020) conducted the only in vivo study in this group. They used cyclophosphamide, a chemotherapy drug that suppresses immune function, to create immunosuppressed mice. These mice received oral Auricularia auricula polysaccharides and were compared against immunosuppressed controls and healthy controls.^[6]

Polysaccharide-treated mice showed recovery of immune organ indexes (spleen and thymus weights relative to body weight), which cyclophosphamide had reduced. Serum levels of IgA, IgG, and IgM increased toward normal levels. Pro-inflammatory cytokines (TNF-alpha, IFN-gamma, IL-2) also recovered. Additionally, the study profiled gut microbiota and found that polysaccharide treatment restored microbial diversity that cyclophosphamide had disrupted, increasing Lactobacillus and Bacteroides populations.^[6]

This study is more clinically relevant than the cell culture experiments because it demonstrates immune recovery in a living system after oral administration. The cyclophosphamide model is specifically relevant to cancer patients receiving chemotherapy, who experience immune suppression as a side effect.

Several aspects of the Kong et al. design strengthen its findings. The study included multiple dosage groups (200 and 400 mg/kg/day), allowing dose-response assessment. Both doses produced measurable effects, with the higher dose generally showing stronger immune recovery. The gut microbiota analysis added mechanistic depth: polysaccharides may stimulate immunity partly by serving as prebiotics for beneficial bacteria that themselves produce immunomodulatory metabolites (short-chain fatty acids, for example).

The limitations are the short duration (14 days of treatment) and the use of immunosuppression by a single chemical agent, which does not replicate the chronic, multifactorial immunosuppression seen in human disease. Cyclophosphamide primarily destroys rapidly dividing immune cells, while real-world immune compromise (from aging, chronic disease, or sustained stress) involves fundamentally different mechanisms that this model does not address. For how Auricularia polysaccharides affect gut bacteria beyond immune contexts, see Auricularia polysaccharides and glucose metabolism, which covers microbiome effects in diabetic models.

Structural requirements for immune activation

Across these studies, a consistent pattern emerges about which polysaccharide features drive macrophage activation.

Negative surface charge is essential. Perera et al. (2018) showed that removing carboxylic acid or O-acetyl groups destroyed activity. Nguyen et al. (2012) showed that adding sulfate groups enhanced it. Both modifications alter the electrostatic profile of the molecule, suggesting that TLR4 recognizes Auricularia polysaccharides partly through charge complementarity.^[2][4]

Mannose content correlates with activity. The glucuronoxylomannan fraction studied by Perera's group had mannose as the dominant sugar (approximately 65% of the monosaccharide composition). Bao et al.'s galactan had mannose as a major component. This does not prove mannose is the active determinant, but it narrows the structural candidates.

Molecular weight varies across preparations. Bao et al. used a 23.51 kDa fraction. Perera's glucuronoxylomannan was larger (over 70 kDa). Both showed activity, suggesting that a minimum molecular weight threshold exists but a single optimal size does not. The relationship between polysaccharide size and immune activity is not monotonic: very small fragments lose the three-dimensional structure that receptors recognize, while very large molecules may have bioavailability limitations.

Beta-glucan content is relevant but not the whole story. Nilkhet et al. (2024) found that macrophage activation correlated with the beta-glucan content of their crude polysaccharide preparations in a dose-dependent manner.^[5] Beta-glucans are well-established immunomodulators across many mushroom species. However, the glucuronoxylomannan studied by Perera's group is not a beta-glucan. It is a heteropolysaccharide with a mannose backbone. This means Auricularia contains at least two structurally distinct polysaccharide classes that activate macrophages, possibly through the same TLR4 receptor but with different binding modes.

What cell culture studies miss

RAW264.7 macrophages in a dish receive polysaccharides directly in their growth media at precisely controlled concentrations. Human macrophages in tissue never encounter this scenario. Orally consumed polysaccharides must survive gastric acid, resist enzymatic degradation, cross the intestinal barrier (or interact with gut-associated immune tissue), and reach tissue-resident macrophages in sufficient concentration to trigger activation.

None of the six studies (including Kong et al.'s oral dosing study) measured polysaccharide concentrations in tissue. The Kong study demonstrated a systemic immune effect from oral polysaccharides, but whether this occurred through direct macrophage activation, through gut-associated lymphoid tissue stimulation, or through microbiome-mediated indirect effects was not distinguished.

The endotoxin tolerance finding from Perera et al. (2020) raises a practical question. If Auricularia polysaccharides induce TLR4 tolerance, chronic consumption might actually dampen rather than enhance the macrophage response to real bacterial infections. This possibility has not been tested but is mechanistically plausible.

The Bottom Line

Six preclinical studies demonstrate that Auricularia polysaccharides activate macrophages through TLR4/NF-kB signaling, enhancing phagocytosis, nitric oxide production, and pro-inflammatory cytokine release. Structural features (carboxylic acid groups, O-acetyl groups, sulfation) determine potency. One in vivo study showed immune recovery in immunosuppressed mice after oral administration. All evidence remains preclinical, and whether oral Auricularia consumption achieves macrophage-activating concentrations in human tissue is unknown.

Frequently Asked Questions

Do Auricularia polysaccharides activate macrophages?

Yes, in laboratory cell culture studies. Polysaccharides from both Auricularia auricula and Auricularia polytricha activate RAW264.7 mouse macrophages, increasing phagocytosis, nitric oxide production, and cytokine secretion (TNF-alpha, IL-6, IL-1beta). Perera et al. (2020) showed this occurs through TLR4 receptor binding and downstream NF-kB signaling. All evidence is from cell culture or animal models.

How do wood ear mushroom polysaccharides boost immune function?

Wood ear polysaccharides bind to TLR4 receptors on macrophage surfaces, triggering a signaling cascade through MAPK, PKC-alpha, and NF-kB that activates antimicrobial gene expression (Perera et al., 2020). This increases phagocytic capacity (the ability to engulf pathogens), nitric oxide production, and secretion of pro-inflammatory cytokines that recruit additional immune cells. Sulfated forms show enhanced potency (Nguyen et al., 2012).

Can Auricularia polysaccharides help with immune suppression from chemotherapy?

One animal study tested this directly. Kong et al. (2020) gave oral Auricularia polysaccharides to cyclophosphamide-immunosuppressed mice and measured recovery of spleen and thymus indexes, serum immunoglobulin levels (IgA, IgG, IgM), and pro-inflammatory cytokines over 14 days. Treated mice showed partial immune recovery compared to untreated immunosuppressed controls. No human trial has tested this application.

What makes Auricularia polysaccharides immunostimulatory?

Structural analysis shows that negative surface charge is critical. Perera et al. (2018) demonstrated that removing carboxylic acid or O-acetyl groups from Auricularia glucuronoxylomannan abolished immunostimulatory activity. Nguyen et al. (2012) showed that adding sulfate groups enhanced it. These charged groups likely facilitate binding to the TLR4/MD2 receptor complex on macrophages.

Do Auricularia polysaccharides have anti-cancer effects through macrophage activation?

Nilkhet et al. (2024) showed that Auricularia polytricha polysaccharides polarized macrophages to the pro-inflammatory M1 phenotype. Media from these activated macrophages reduced human breast cancer cell viability by 40-60% in culture. This is an indirect mechanism where polysaccharides activate immune cells, and those immune cells then suppress cancer growth. Whether this cascade functions in a living tumor microenvironment is untested.

Is there a clinical trial for Auricularia and immune function?

As of 2026, no published randomized controlled trial has tested Auricularia polysaccharides specifically for immune enhancement in humans. All six studies in the research base used mouse macrophage cell lines (RAW264.7) or mouse models. Human pharmacokinetic data showing whether orally consumed Auricularia polysaccharides reach immune cells at active concentrations does not exist.

Sources & References

1. 1RTHM-00649·Perera, Namal et al. (2020). “Phagocytosis enhancement, endotoxin tolerance, and signal mechanisms of immunologically active glucuronoxylomannan from Auricularia auricula-judae..” International journal of biological macromolecules.Study breakdown →PubMed →↩
2. 2RTHM-00525·Perera, Namal et al. (2018). “Carboxylic and O-acetyl moieties are essential for the immunostimulatory activity of glucuronoxylomannan: a novel TLR4 specific immunostimulator from Auricularia auricula-judae..” Chemical communications (Cambridge.Study breakdown →PubMed →↩
3. 3RTHM-00607·Bao, Zhijie et al. (2020). “Isolation, purification, characterization, and immunomodulatory effects of polysaccharide from Auricularia auricula on RAW264.7 macrophages..” Journal of food biochemistry.Study breakdown →PubMed →↩
4. 4RTHM-00259·Nguyen, The Luong et al. (2012). “Immuno-enhancing activity of sulfated Auricularia auricula polysaccharides..” Carbohydrate polymers.Study breakdown →PubMed →↩
5. 5RTHM-00897·Nilkhet, Sunita et al. (2024). “M1 macrophages polarized by crude polysaccharides isolated from Auricularia polytricha exhibit anti-tumor effect on human breast cancer cells..” Scientific reports.Study breakdown →PubMed →↩
6. 6RTHM-00628·Kong, Xianghui et al. (2020). “Effects of Polysaccharides From Auricularia auricula on the Immuno-Stimulatory Activity and Gut Microbiota in Immunosuppressed Mice Induced by Cyclophosphamide..” Frontiers in immunology.Study breakdown →PubMed →↩